INM
NASDAQ · Pharmaceuticals
Inmed Pharmaceuticals Inc
$0.70
+0.01 (+1.07%)
Open$0.69
Previous Close$0.69
Day High$0.70
Day Low$0.68
52W High$7.98
52W Low$0.73
Volume—
Avg Volume77.5K
Market Cap2.39M
P/E Ratio—
EPS$-4.08
SectorPharmaceuticals
Analyst Ratings
Strong Sell
8 analysts
Price Target
+4,714.7% upside
Current
$0.70
$0.70
Target
$33.65
$33.65
$24.21
$33.65 avg
$46.15
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 15.06M | 9.10M | 790.8K |
| Net Income | -24,869,113 | -13,522,354 | 172.0K |
| Profit Margin | -165.1% | -156.9% | 21.8% |
| EBITDA | -23,476,807 | -13,474,484 | 218.3K |
| Free Cash Flow | — | — | 109.5K |
| Rev Growth | +65.5% | +65.5% | +11.4% |
| Debt/Equity | — | — | 0.10 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $916.31 | +1.47% | 46.4 | 957.52B |
| JNJ | Johnson & Johnson | $239.93 | +1.98% | 22.2 | 594.00B |
| MRK | Merck & Co. Inc. | $119.37 | +2.58% | 16.5 | 301.17B |
| PFE | Pfizer Inc. | $27.28 | +1.19% | 19.7 | 153.36B |
| BMY | Bristol-Myers Squibb Co | $58.94 | +2.70% | 16.5 | 116.58B |
| ZTS | Zoetis Inc | $116.71 | +0.67% | 21.5 | 57.37B |